Just as an adjunct to my previous post. I have been playing with...

Just as an adjunct to my previous post. I have been playing with Ai Chat to work out a price BP may consider paying.

I suggested gross revenue of $6 billion [US] using Relyvrio as an example. I suggested a net profit of 1.2 billion a year. [Which seems to be the norm from what I have read] I did not include ODD or patent protection until 2033, deciding to keep it simple. Nor did i suggest Monepantel should eclipse the uptake of Relyvrio and that Relyvrio had a 43% drop out rate due to side effects, or that patients may be on Monepantel for longer periods, thus increasing uptake/sales.

The suggested value that a BP may consider is around $2.5 Billion US. Or $3.7 billion AUD.

I probably have 2 much time on my hands. And am in no way an accountant, so don't hold me to it.


Cheers